在老鼠心脏中,复星减弱了因衰老引起的线粒体功能障碍和线粒体介导的亡
Youngju Choi1,2,3, Mi-Hyun No1, Jun-Won Heo4
1Institute of Sports and Arts Convergence (ISAC), Inha University, Incheon 22212, Korea.
Nutrition research and practice
|April 14, 2025
概括
复星补充剂通过减少心脏重塑和改善线粒体功能,有利于心脏衰老. 这种天然化合物对抗与年龄相关的细胞损伤,并保护心脏病.
科学领域:
- 心血管科学 心血管科学
- 老年学是一门学科.
- 线粒体生物学 线粒体生物学
背景情况:
- 复星是一种天然的多,具有抗氧化和抗炎性质.
- 心血管疾病通常与衰老过程有关.
- 衰老会影响心脏结构和功能,包括线粒体健康.
研究的目的:
- 为了研究复星对抗年龄引起的心脏重塑的保护作用.
- 评估复星对心脏衰老中的线粒体功能障碍的影响.
- 为了确定复星是否抑制老年心脏组织中线粒体介导的亡.
主要方法:
- 用了32只雄性Fischer 344大鼠,分为年轻和老年群体,有和没有白醇治疗 (50毫克/公斤/天6周).
- 分析了来自左心室的心肌纤维.
- 评估了线粒体功能和亡途径.
主要成果:
- Ресвератрол显著降低了老老老鼠的心脏缩和重塑.
- 它改善了因衰老引起的线粒体功能障碍,包括减少氧气呼吸和增加过氧化排放.
- 通过改变Bax/Bcl-2比率,减少线粒体透性过渡孔口的开放,并降低分裂的caspase-3水平,resveratrol抑制了线粒体介导的亡.
结论:
- 复星治疗为心脏老龄化提供了保护性益处.
- 它有效地减轻了与年龄有关的心脏重塑.
- 复星可以改善线粒体功能障碍并抑制细胞亡,突出显示其在衰老中的心脏保护潜力.
相关概念视频
Mitochondria
8.9K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
8.9K
Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321


